Finance
Investor Growth Capital is new principal owner of biomaterials producer
Published in Drug Week, January 27th, 2006
This capital infusion will fund continued development of Doxa's biomaterials, primarily for use in orthopedics.
Doxa develops new biomaterials for medical use. Since 2002 efforts have been concentrated on the rapidly growing orthopedics sector where treatment of vertebral fractures has advanced most. In 2005 Doxa has conducted clinical trials with very good results. All patients with vertebral fractures felt significantly less pain. Operations are performed using minimal invasive surgery, which also leads to...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2006-01-27)
More Articles from Drug Week
- Cancer Therapy
Cervical cancer vaccine candidate induced a higher immune response in young girls - Cancer Therapy
Supplemental BLA submitted for Avastin in relapsed metastatic colorectal cancer - Drug Development
High response rates reported in use of single agent Treanda in non-Hodgkin lymphoma - Pain Management
U.S. FDA accepts investigational new drug application for Sativex - Rotavirus
Vaccine candidate shown effective against rotavirus disease in infants - Abortion
Studies evaluate misoprostol use to terminate pregnancies in Latin America - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
